The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|September 1, 2017
- Pharmaceutical Technology-09-01-2017
- Volume 2017 Supplement
- Issue 4
Pharmaceutical Technology, 2017 APIs, Excipients, and Manufacturing Supplement (PDF)
Click the title above to open the Pharmaceutical Technology 2017 APIs, Excipients, and Manufacturing Supplement issue in an interactive PDF format.
Advertisement
Articles in this issue
about 9 years ago
Four Challenges for Pulmonary Drug Deliveryabout 9 years ago
Applying QbD in Process Developmentabout 9 years ago
A Multifunctional Mineral Excipientabout 9 years ago
New Technologies Optimize API and Drug Product Manufacturingabout 9 years ago
Why Bottles with Desiccant Outperform Foil-Foil Blister Packagingabout 9 years ago
How to Get the Most from Regulatory Outsourcingabout 9 years ago
Cleaning Validation for APIsabout 9 years ago
Speeding Up Formulation DevelopmentAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement